Olodaterol monotherapy set for Phase III testing in COPD
This article was originally published in Scrip
Boehringer Ingelheim has completed the Phase II programme of olodaterol monotherapy in patients with chronic obstructive pulmonary disease (COPD) and has "set the stage" for the drug to be tested as a monotherapy in Phase III.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.